$EARS Does new assets are coming in? Excerpt from last PR: 'We intend to develop a proprietary NKCC1 inhibitor through our new subsidiary, Zilentin Ltd., which we recently established in order to bundle our activities and assets within the therapeutic areas of tinnitus and hearing loss.” Something is moving here 😉
  • 3
  • 1